For Patients & Caregivers
Transfer factors have not been shown to treat or prevent cancer.
Transfer factors are a group of proteins produced by cells of the immune system. Some studies have shown that transfer factors can be used to treat herpes, infections in children, chronic fatigue syndrome, and yeast infections. They may also boost the immune system in patients with AIDS. More research is needed to determine the anticancer effects of transfer factors.
To treat cancer
Although some studies have shown that transfer factors can have some positive effects in cancer patients, further research is needed to confirm such observations.
To treat multiple sclerosis
This use is not supported by scientific evidence.
To treat HIV/AIDS
One study showed that transfer factors increased the number of white blood cells in patients with AIDS.
To treat herpes and Epstein-Barr virus
Studies have shown some signs of efficacy in treating herpes.
To treat hepatitis (inflammation of liver)
Transfer factors were not effective in treating hepatitis.
To treat asthma
Some studies have shown that transfer factor does not benefit patients with asthma.
To treat chronic fatigue syndrome
Transfer factor was shown to have positive effects in the treatment of chronic fatigue syndrome.
For Healthcare Professionals
Transfer factors are a complex group of more than 200 highly polar, hydrophilic, low molecular weight (<12,000 Da) proteins produced in small quantities by lymphoid cells (1). They can be extracted from human or animal white blood cells, or cloned lymphocytes grown in vitro, colostrum, and egg yolk. The parent lymphocyte’s delayed-type hypersensitivity and cell-mediated immunity is passed along to non-immune recipients, and appears to function across species.
In animal studies, transfer factors were shown to reduce tumor size and increase peripheral blood T-lymphocyte counts (21).
In humans, transfer factors appear to be well tolerated and have shown some efficacy in the treatment of herpes (2), acute infection in children (3), chronic fatigue syndrome (4), and Candidiasis (5). One study showed effectiveness in increasing white blood cells, CD8 lymphocytes and interleukin 2 levels among patients with HIV (6). However, transfer factors are ineffective in treating hepatitis (7), multiple sclerosis (8), extrinsic bronchial asthma (9), human warts (10), juvenile rheumatoid arthritis (28), and acne vulgaris (11).
Studies in various cancers have shown that transfer factors are ineffective in treating malignant melanoma (12), nasopharyngeal carcinoma (13), bronchogenic carcinoma (14), Hodgkin’s disease (15), osteogenic sarcoma (16), and mycosis fungoides (17). However, in a study of children with leukemia, immunization with transfer factors conferred protection against varicella-zoster infection (20). Other trials have shown increased survival rates among patients with Stage I adenocarcinoma of the lung (18) and Stage I cervical cancer (19).
Overall, there is a paucity of large randomized controlled clinical trials, and a need for further research into the effectiveness of transfer factors.
Transfer factors contain many molecules, some of which act in an antigen-specific manner, while others have been shown to have immunomodulating capabilities (1). Human leukocyte dialysates (DLE) contain low molecular peptides that were characterized in the late 1980s as amino terminal ends of enkephalins. A low molecular weight sub fraction derived from DLE, IMREG-1, has been shown to enhance cell-mediated immunity (22).
In vitro studies have shown that cells of both murine recipients and humans treated for herpes zoster virus infection secrete gamma-interferon in response to transfer factors (2) (23). Studies have also suggested that production of transfer factors, but not their immunologic activities, is regulated by immune response genes (24).